Microdosing Ketamine for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Microdosing Ketamine for Health & Longevity

Created on 08/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Relief of low mood within hours is supported by controlled human research; whether the very small amounts used at home reproduce it is unsettled, and smaller amounts appear to work less well. Claims beyond mood rest on thinner ground. Detachment, raised blood pressure and nausea pass quickly, but the safe ceiling for repeated home use has never been mapped. (Full Review)

Protocol

Very-low-dose sublingual protocol (the original approach)
10 mg, every 2–3 days or weekly
Racemic ketamine from a 100 mg/mL solution, held under the tongue for 5 minutes. Explicitly sub-perceptual.
Compounded troche protocol (the common telehealth approach)
25–100 mg, one to three times weekly
Racemic ketamine lozenge or rapid-dissolve tablet held sublingually for 10–15 minutes, titrated from a lower starting dose.
Best time of day
Evening, at rest
Places the sedative window outside working and driving hours. Activation instead of sedation shifts dosing to late afternoon.
Time to effect
Depressive symptoms
Hours to days
Mood effects appear within hours of the first effective dose and are usually evident within 24 hours.
Sustained mood benefit
2–4 weeks
Sustained benefit from a repeated schedule generally becomes apparent over 2–4 weeks.
Anxiety reduction
Within 12 hours
Onset within hours in pooled trials; effects are not established beyond two weeks.

Benefits

Contraindications
  • Uncontrolled hypertension (above 160/100 mmHg)
  • Intracranial aneurysm or arteriovenous malformation
  • Unstable angina or myocardial infarction within 90 days
  • New York Heart Association Class III–IV heart failure
  • Personal or first-degree family history of schizophrenia or other primary psychotic disorder
  • Current mania
  • Active substance use disorder (dissociatives, alcohol)
  • Hepatic impairment, Child-Pugh Class B or C
  • Pre-existing interstitial cystitis or unexplained lower urinary tract symptoms
  • Pregnancy and breastfeeding
  • Severe untreated obstructive sleep apnea
  • Cannot remain safely at rest, unable to drive, for at least two hours after dosing
    •
Key Interactions
  • Benzodiazepines (lorazepam, diazepam, clonazepam)
  • Opioid antagonists (naltrexone, naloxone)
  • CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice)
  • CYP3A4 and CYP2B6 inducers (rifampicin, carbamazepine, St John's wort)
  • Sympathomimetics and stimulants (amphetamine, methylphenidate, high-dose caffeine)
  • Other central nervous system depressants (alcohol, opioids, gabapentinoids, sedating antihistamines)
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline)
  • Supplements with additive blood-pressure or sedative effects (nitrate, magnesium, hibiscus, valerian, kava, high-dose melatonin)
  • Supplements with additive effects on the same pathway (magnesium, zinc, agmatine, rapamycin)
  • Other intervention interactions (psychedelic-assisted therapy, transcranial magnetic stimulation, electroconvulsive therapy)

Risk & Side Effects

  • High: Dissociation and perceptual disturbance; transient increase in blood pressure and heart rate; nausea, vomiting, dizziness and sedation; misuse, tolerance and dependence potential
  • Medium: Ketamine-associated uropathy; cognitive impairment with frequent or high-dose use; hepatobiliary injury and liver enzyme elevation; hazards specific to unsupervised at-home administration
  • Low: Tachyphylaxis and diminishing response; precipitation of mania, psychosis or persistent perceptual disturbance; disrupted sleep and next-day activation; raised intraocular and intracranial pressure
  • Speculative: Emotional blunting with sustained daily use; unknown effects of decade-scale exposure

Monitoring

Marker Target Why
Blood Pressure 110–120 / 70–80 mmHg at rest Ketamine's main cardiovascular effect; defines the safe ceiling
Resting Heart Rate 50–70 bpm Tracks sympathetic activation and cumulative stimulant load
ALT and AST ALT 10–26 U/L (women), 10–33 U/L (men); AST 10–26 U/L Detects the liver-cell injury seen with repeated exposure
GGT Below 20 U/L (women), below 25 U/L (men) Most sensitive early marker of biliary irritation
Serum Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Detects upper urinary tract involvement if bladder injury progresses
Urinalysis (dipstick and microscopy) No blood, no leukocytes, no protein Earliest objective sign of bladder injury, reversible if caught early
hs-CRP Below 1.0 mg/L Baseline inflammatory status; context for the speculative anti-inflammatory claim
Fasting Glucose and HbA1c Glucose 75–86 mg/dL; HbA1c 4.8–5.2% Ketamine acutely raises glucose; confirms no drift with repeated use

Cadence: Blood pressure before and 20 minutes after every dose for the first month, then monthly; urinary symptom review at 4 weeks, then every 3 months; blood panel at 3 months, then every 6 months; cognitive baseline annually, or sooner over 65.

Qualitative Assessment

  • Mood level and stability: day-to-day variability, not just how low or high
  • Sleep quality and continuity: time to fall asleep, night wakings, how rested the morning feels
  • Cognitive clarity: word-finding, short-term memory, holding a complex task in mind
  • Urinary symptoms: frequency, urgency and suprapubic discomfort, asked explicitly
  • Emotional range: whether positive and negative feelings are both intact, or affect is flattening
  • Relationship to the dose: doses taken as scheduled, anticipation between doses, resistance to stopping
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.